Over time, about one-third of all MDS cases evolve to become AML. The risk of developing AML depends largely on the MDS subtype.
During this program, Dr. Ross Levine from Memorial Sloan Kettering Cancer Center explains the relationship between MDS and AML and how the progression occurs. He describes how each disease is diagnosed and the symptoms you may experience. Dr. Levine concludes with the latest and emerging treatment options and practical tips for taking charge of your care.
By the end of this program, you will understand:
- The prognosis from MDS to AML
- Genetic mutations associated with MDS and AML
- Questions you should ask your healthcare team